Treatment with Ponvory (ponesimod) for up to 13 years was associated with sustained low disease activity in adults with relapsing-remitting multiple sclerosis (RRMS), with relapse rates and brain lesion activity decreasing over time. That’s according to new data from a completed Phase 2b clinical trial (NCT01006265) and its long-term…
Discussion
Some lifestyle habits, such as engaging in physical activity and not smoking, may provide the greatest health benefits earlier in the course of multiple sclerosis (MS), while others, such as eating a healthy diet, may be of more help to those who have been living with the disease for…
Discussion
Immunic says it’s on track to announce early data by year’s end from twin late-stage trials testing vidofludimus calcium (IMU-838) — an oral therapy believed to have both anti-inflammatory and neuroprotective properties — in people with relapsing forms of multiple sclerosis (MS). The top-line results from the…
Discussion
A trio of scientists in Australia has developed a mathematical model that can be used to help understand disease activity patterns in people with multiple sclerosis (MS). The model uses two overarching variables — inflammation and myelin damage — to describe how relapses and stable disease occur in…
Discussion
A drug used to prevent stroke complications may help preserve myelin, the protective coating around nerve fibers that is damaged in multiple sclerosis (MS), according to a review of data from animal studies. The treatment, nimodipine, was also associated with reduced inflammation, nerve damage, and disease severity in several…
Get regular updates to your inbox.
